High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins

Antimicrob Agents Chemother. 1996 Jan;40(1):218-20. doi: 10.1128/AAC.40.1.218.

Abstract

We treated nine patients (10 episodes) with meningitis caused by Streptococcus pneumoniae isolates with decreased susceptibilities to broad-spectrum cephalosporins with high doses of cefotaxime (300 mg/kg of body weight per day; maximum dose, 24 g/day). Early adjunctive therapy with dexamethasone was also administered. Cefotaxime MICs were 0.5 (three episodes), 1 (five episodes), and 2 (two episodes) micrograms/ml, and MBCs ranged from 1 to 4 micrograms/ml. Therapy was well tolerated, and all patients experienced prompt clinical improvement. One patient died 8 days after the end of therapy, the central nervous system infection had already been cured, and the remaining patients recovered without relapses.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cefotaxime / administration & dosage
  • Cefotaxime / cerebrospinal fluid
  • Cefotaxime / therapeutic use*
  • Cephalosporin Resistance*
  • Cephalosporins / administration & dosage
  • Cephalosporins / cerebrospinal fluid
  • Cephalosporins / therapeutic use*
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Meningitis, Pneumococcal / drug therapy*
  • Meningitis, Pneumococcal / epidemiology
  • Meningitis, Pneumococcal / microbiology
  • Microbial Sensitivity Tests
  • Middle Aged
  • Spain / epidemiology

Substances

  • Cephalosporins
  • Cefotaxime